Date
12 May 2026

Time
 11:00-12:30 ET | 15:00-16:30 GMT | 16:00-17:30 CET

Key features

With USP <665> becoming official in May 2026, biopharma companies are asking the same questions:

• What data are really expected for single use components?

• How does USP <665> align with long standing BioPhorum extractables best practices?

• Where is flexibility still appropriate—and where are regulators drawing firmer lines?

Join us to explore how effective risk assessment, high‑quality supplier data, and alignment with BioPhorum best practices enable companies to meet USP <665> expectations without unnecessary repeat testing—while still maintaining rigorous control over extractables and leachables (E&L) risk.

Building on insights from BioPhorum Drug Substance’s latest publication, this webinar will equip you with the knowledge to strengthen regulatory preparedness, enhance internal decision-making, and foster more productive collaboration between end users, suppliers, and regulators as the industry moves into the USP <665> era.